Insider Transactions in Q1 2025 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,532
-0.92%
|
$27,064
$2.48 P/Share
|
|
Jan 02
2025
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,149
+1.95%
|
-
|
|
Jan 02
2025
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,575
-9.14%
|
$17,150
$2.48 P/Share
|
|
Jan 02
2025
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,150
+16.21%
|
-
|
|
Jan 02
2025
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,059
-5.88%
|
$10,118
$2.48 P/Share
|
|
Jan 02
2025
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,200
+13.31%
|
-
|
|
Jan 02
2025
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,914
-3.88%
|
-
|
|
Jan 02
2025
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,380
+7.03%
|
-
|
|
Jan 01
2025
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,904
-0.27%
|
$7,808
$2.48 P/Share
|
|
Jan 01
2025
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.65%
|
-
|
|
Jan 01
2025
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,430
-3.23%
|
$4,860
$2.48 P/Share
|
|
Jan 01
2025
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.07%
|
-
|